PharmaCorp Rx (TSXV:PCRX) Accounts Receivable: C$1.40 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:PCRX PharmaCorp Rx Inc TSXV:PCRX
38 GF Score
Price C$0.43
! 2 Warning Signs
View Full Analysis

What is PharmaCorp Rx Accounts Receivable?

PharmaCorp Rx TSXV:PCRX -3.93% 38 Accounts Receivable is C$1.40 Mil as of Jun. 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. PharmaCorp Rx's accounts receivables for the quarter that ended in Jun. 2026 was C$1.40 Mil.

Accounts receivable can be measured by Days Sales Outstanding. PharmaCorp Rx's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 16.57.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. PharmaCorp Rx's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was C$0.09.

PharmaCorp Rx Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

PharmaCorp Rx's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=1.403/7.728*91
=16.57

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), PharmaCorp Rx's accounts receivable are only considered to be worth 75% of book value:

PharmaCorp Rx's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(24.015+0.75 * 1.403+0.5 * 3.128-11.176
-0-0.393)/174.082
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

PharmaCorp Rx Accounts Receivable Related Terms

PharmaCorp Rx Accounts Receivable Historical Data

* Premium members only.

The historical data trend for PharmaCorp Rx's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCorp Rx Accounts Receivable Chart

PharmaCorp Rx Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Receivable
0.00 0.00 0.00 0.33 1.22

PharmaCorp Rx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.79 1.22 1.19 1.40
TSXV:PCRX
38GF Score
PharmaCorp Rx Inc TSXV:PCRX
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCorp Rx Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of C$1.40 Mil mean?
PharmaCorp Rx (TSXV:PCRX) has a Accounts Receivable of C$1.40 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on PharmaCorp Rx and its competitors.
Is PharmaCorp Rx's Accounts Receivable too high?
PharmaCorp Rx's current Accounts Receivable is C$1.40 Mil. Overall, PharmaCorp Rx has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's Accounts Receivable compare to competitors?
PharmaCorp Rx's Accounts Receivable of C$1.40 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Healthcare Providers & Services company?
A good Accounts Receivable depends on the Healthcare Providers & Services industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on PharmaCorp Rx and its competitors. PharmaCorp Rx's current Accounts Receivable is C$1.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current Accounts Receivable of C$1.40 Mil. The current Accounts Receivable is C$1.40 Mil. PharmaCorp Rx's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current Accounts Receivable is C$1.40 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCorp Rx Business Description

Address 303 Wellman Lane, Suite 203, Saskatoon, SK, CAN, S7T 0J1
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
38GF Score

Get the complete analysis for TSXV:PCRX

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.43
Price